ArticleThe Journal of infectious diseases2019
Analysis of IgG Anti-HEV Antibody Protective Levels During Hepatitis E Virus Reinfection in Experimentally Infected Rhesus Macaques.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Hepatitis E virus seroprevalence in South Africa: a multi-site study among HIV-negative and HIV-positive adults and age-stratified children (2-17 Years).BMC infectious diseases · 2026Article
- Diagnostic Performance and Kinetics of Hepatitis E Viral RNA and IgM Antibody Test Positivity in a Genotype 1 Outbreak in South Sudan.The Journal of infectious diseases · 2026Article
- Performance of Elecsys Anti-HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- Hepatitis E virus neutralization by porcine serum antibodies.Journal of clinical microbiology · 2023Article
- [Laboratory diagnosis of hepatitis type E].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- The first reported hepatitis E outbreak in a food manufacturing factory: Korea, 2022.Osong public health and research perspectives · 2023Article
- Immunobiology and Host Response to HEV.Advances in experimental medicine and biology · 2023Article
- Hepatitis E in Bangladesh: Insights From a National Serosurvey.The Journal of infectious diseases · 2021Article
- Review
- Current Paradigm of Hepatitis E Virus Among Pediatric and Adult Patients.Frontiers in pediatrics · 2021Review
- Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin.Transfusion · 2020Article
- Hepatitis E Virus: How It Escapes Host Innate Immunity.Vaccines · 2020Review
- Risk of Hepatitis E among Persons Who Inject Drugs in Hong Kong: A Qualitative and Quantitative Serological Analysis.Microorganisms · 2020Article
- Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study.Scientific reports · 2020Article
- Implications of Hepatitis E Virus in Blood Transfusions, Hemodialysis, and Solid Organ Transplants.Medicina (Kaunas, Lithuania) · 2020Review
- Transcriptome analysis in rhesus macaques infected with hepatitis E virus genotype 1/3 infections and genotype 1 re-infection.PloS one · 2020Article
- Reply to Sayed.The Journal of infectious diseases · 2019Article
- Chronic hepatitis E after kidney transplantation with an antibody response suggestive of reinfection: a case report.BMC infectious diseases · 2019Article
Corrections and comments
- Commented on byReply to Sayed.2019
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSecondary spread of hepatitis E virus (HEV) infection occurs often in endemic settings in developing countries. The host immune signatures contributing to protection against subsequent HEV reinfection are unknown.
methodsTwelve seroconverted rhesus macaques were reinoculated with homologous HEV genotype 1 (gt1, Sar-55) and followed for 115 days. HEV RNA, HEV-specific T-cell responses, IgG anti-HEV antibody, and the IgG anti-HEV avidity index were tested.
resultsFour animals with baseline IgG anti-HEV levels from 1.5 to 13.4 World Health Organization (WHO) U/mL evidenced reinfection as determined by HEV RNA in stool, and increase in IgG anti-HEV levels between 63- and 285-fold (P = .003). Eight animals with baseline IgG anti-HEV levels from 2.8 to 90.7 WHO U/mL did not develop infection or shed virus in feces, and IgG anti-HEV antibody levels were unchanged (P = .017). The 4 reinfected animals showed a lower HEV-IgG avidity index (average 35.5%) than the 8 protected animals (average 62.1%). HEV-specific interferon-gamma-producing T cells were 2-fold higher in reinfected animals (P = .018).
conclusionsPreexisting antibody and high IgG avidity index (>50%) are important factors for protection against HEV reinfection. HEV-specific T-cell responses were elevated in reinfected animals after subsequent exposure to HEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.